oral capsule that’s prescribed for certain lung conditions in adults

First approved by the FDA in 2014 as a treatment for adults with IPF
In 2019, OFEV became the first FDA-approved therapy to slow the rate of decline in lung function in adults with SSc-ILD
OFEV is also the first FDA-approved treatment for adults with chronic ILD with worsening fibrosis

What I did

Client: Boehringer-Ingelheim

Branded Project: https://www.ofev.com/

Deliverables:

  • Website Design
    (ChILD indication page launching on Jan 2024)

Project type and deliverables:

  • UX Design

  • UI Prototype (InVision)

  • Interaction Design

  • UI Design (Client: Sketch,
    Wunderman Thompson: Figma)

  • Product Owner

“If approved, OFEV would be the first and only approved treatment for these patients, helping to address an unmet need”

Breakthrough

Nintedanib Under Review for Children With Fibrosing Interstitial Lung Disease

The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for nintedanib for children and adolescents 6 to 17 years of age with fibrosing interstitial lung disease (ILD)

Problem

Orphan Disease

Children’s Interstitial Lung Disease (chILD) is a group of rare pediatric lung diseases. There are more than 30 disorders included under the chILD umbrella.

The Orphan Drug Act defines a rare disease as a disease or condition that impacts fewer than 200,000 people in the U.S.

chILD disorders are the rarest rare diseases, orphan diseases, with less than 10,000 estimated cases in the U.S.

Due to the rarity of chILD, many families report knowing little about the disease, both at the time of diagnosis and during follow-up

Problem

Finding Unknown

While PF-ILDs in adults have been thoroughly studied through several clinical trials resulting in approved treatment therapies., most of what is known about lung fibrosis in children comes from studies with adults*

There is little research on the experiences of caregivers of patients with chILD (particularly those of older children)

Problem

Unexplained Fear

In caregivers of younger patients with chILD, up to 91% report anxiety, indicating a deep need for clear communication and support.

Caregivers (as the average age of a mother with a newborn is 26, the age range for mothers of a 6-17 year-old may fall between 32-43)

Solution

ChILD Indication Updates

I led the designs for the new proposed OFEV Updates for Future chILD Indication, which will launch by January 2024. Visit OFEV.com for more information.

Contact me if you want to learn more about the process :-)